NeuroPace, Inc.
NPCE
NASDAQ·Healthcare·Medical - Devices·Mkt cap $508.0M
$14.90
▲ +1.02%
P/E
-26.06
Mkt Cap
$508.0M
52-Wk Range
$9.22–$19.60
52-Week Range
$9.22 - $19.60
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 53.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary brain-responsive neuromodulation technology with personalized treatment algorithms
- Continuous brain activity recording and remote monitoring capabilities creating recurring data insights
- Established relationships with hospital facilities and neurology specialists for implant procedures
- Regulatory clearance and clinical evidence supporting RNS System efficacy in medically refractory epilepsy
Bear Case
1 risk
- Above-average volatility (beta 1.9).
Growth
Stable outlook
Expanding patient awareness and adoption among medically refractory epilepsy population
Value
Deep value opportunity - significant discount to Medical Devices peers
Momentum
Stable
-4.7% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying NPCE right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 3, 2026
AUG 11, 2026
Reported EPS of -$0.18 vs -$0.22 consensus (+17.4% surprise). Revenue of $22.8M vs $22.6M expected (+0.9%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+17.4%
Revenue trend · last 8Q
—
+19%
+24%
+22%
+30%
+24%
-2%
-3%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$21.1M
$21.5M
$22.5M
$23.5M
$27.4M
$26.6M
$22.1M
$22.8M
Margins · last 8Q
Gross
82.8%
Operating
-22.5%
Profit
0.0%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · $20.00 · May 15, 2026
vs Industry
How NPCE stacks vs Medical - Devices
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related